- ►diabetesjournals.org RS Rosenson, JD Otvos, J Hsia - Diabetes Care, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS Patients with dyslipidemia and the metabolic
syndrome (n = 318) were randomly assigned in a double-blind study comparing 10
mg rosuvastatin (RSV), 10 mg atorvastatin, or placebo daily for 6 weeks. ... Cited by 1 - Related articles - All 2 versions
T Zhu, WM Awni, B Hosmane, MT Kelly, DJ … - The Journal of Clinical Pharmacology, 2009 - jclinpharm.highwire.org ABT-335 is the choline salt of fenofibric acid under clinical development as a
combination therapy with rosuvastatin for the management of dyslipidemia.
ABT-335 and rosuvastatin have different mechanisms of actions and exert ... Cited by 4 - Related articles - All 4 versions
T Filippatos, HJ Milionis - Expert Opin. Investig. Drugs, 2008 - informahealthcare.com Background: Fenofibrate is the most widely used fibrate. Its efficacy and
tolerability in the treatment of hypertriglyceridaemia and combined
hyperlipidaemia have been demonstrated in several clinical trials. ... Cited by 5 - Related articles - All 5 versions
AC Goldberg, HE Bays, CM Ballantyne, MT … - The American Journal of Cardiology, 2009 - Elsevier In patients with mixed dyslipidemia characterized by increased triglycerides
(TG), decreased high-density lipoprotein (HDL) cholesterol, and increased
low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering ... Cited by 5 - Related articles - All 27 versions
JH Contois, JP McConnell, AA Sethi, G Csako … - Clinical Chemistry, 2009 - Am Assoc Clin Chem Content: Recent data demonstrate that apolipoprotein B (apo B) is a better
measure of circulating LDL particle number (LDL-P) concentration and is a more
reliable indicator of risk than LDL-C, and there is growing support for the ... Cited by 6 - Related articles - All 4 versions
JG Robinson, S Wang, BJ Smith, TA … - Journal of the American College of Cardiology, 2009 - Am Coll Cardio Found Still not a subscriber to JACC Imaging or JACC Interventions? ... Manuscript
received June 16, 2008; revised manuscript received October 6, 2008, accepted
October 7, 2008. ... Objectives: To determine the relationship between ... Cited by 8 - Related articles - All 26 versions
JC Ansquer, C Foucher, P Aubonnet, K Le … - Current pharmaceutical design, 2009 - ingentaconnect.com Abstract: Fibrates are widely prescribed lipid-lowering drug in the treatment of
dyslipidemia. Their main clinical effects, mediated by peroxisome proliferative
activated receptor (PPAR) alpha activation, are a moderate reduction in ... Cited by 7 - Related articles - All 3 versions
JC Hogue, B Lamarche, Y Deshaies, AJ … - Metabolism, 2008 - Elsevier The specific impact of 3-hydroxy-3-methylglutaryl–coenzyme A reductase
inhibitors and fibrates on the in vivo metabolism of apolipoprotein (apo) B has
not been systematically investigated in patients with type 2 diabetes ... Cited by 8 - Related articles - All 17 versions
- ►diabetesjournals.org R Scott, R O'Brien, G Fulcher, C Pardy, M d … - Diabetes Care, 2009 - Am Diabetes Assoc RESULTS—More than 80% of FIELD participants met the ATP III criteria for
metabolic syndrome. Each ATP III feature of metabolic syndrome, apart from
increased waist circumference, increased the absolute risk of CVD events ... Cited by 8 - Related articles - All 3 versions
- ►nursing2008.com KK Ray, CP Cannon, R Cairns, DA Morrow, … - Arteriosclerosis, Thrombosis, and Vascular Biology, 2009 - Am Heart Assoc Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone:
410-528-4050. Permissions: Permissions & Rights Desk, Lippincott Williams &
Wilkins, a division of Wolters ... Prognostic Utility of ApoB/AI, Total ... Cited by 9 - Related articles - All 8 versions
